Combination of intravenous S-ketamine and oral tranylcypromine in treatment-resistant depression: A report of two cases

@article{Bartova2015CombinationOI,
  title={Combination of intravenous S-ketamine and oral tranylcypromine in treatment-resistant depression: A report of two cases},
  author={Lucie Bartova and Sonja Vogl and Mara Stamenkovic and Nicole Praschak-Rieder and Angela Naderi-Heiden and Siegfried Kasper and Matthaeus Willeit},
  journal={European Neuropsychopharmacology},
  year={2015},
  volume={25},
  pages={2183-2184}
}
The Concurrent Treatment With Intravenous Ketamine and an Irreversible Monoamine Oxidase Inhibitor for Treatment-Resistant Depression Without Hypertensive Crises.
TLDR
A pooled analysis of 66 successful coadministrations of IVK and phenelzine in 3 TRD patients, treated at a single center in Edmonton, Alberta, Canada between June 2017 and October 2019, without precipitated HC is presented.
Antidepressant Actions of Ketamine and Its Two Enantiomers
TLDR
Recent findings on the antidepressant actions of two enantiomers of ketamine are discussed, including (R,S), which has been reported to have a greater potency and longer-lasting antidepressant effects than (S)-ketamine in rodent models of depression.
Ketamine: From Abused Drug to Rapid-Acting Antidepressant
TLDR
At present, no effective pharmacotherapy for managing compulsive drug-seeking behavior in patients with ketamine use disorder is available, but treatment that incorporates regular urine screening in addition to medications for psychiatric symptoms and craving may present favorable results.
Rapid antidepressant effect of S-ketamine in schizophrenia
Cardiovascular Effects of Combining Subcutaneous or Intravenous Esketamine and the MAO Inhibitor Tranylcypromine for the Treatment of Depression: A Retrospective Cohort Study
TLDR
Combining esketamine and this MAOI appears to be safe at standard doses, and a significant dose–response relationship between tranylcypromine dose and BP is found, but the dose– response relationship calls for caution with higher doses of tranylCypromine.
Combination of Tranylcypromine and Mirtazapine in Difficult-to-Treat Depression
TLDR
Under tight clinical controls in inpatient setting and after exhausting of alternatives, the combination of tranylcypromine and mirtazapine could be considered in patients, who do not achieve adequate improvement through common treatment options recommended in the guidelines.
Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review
TLDR
Current literature shows that benzodiazepines and probably lamotrigine reduce ketamine’s treatment outcome, which should be taken into account when considering ketamine treatment.
60 Years of Combining Tranylcypromine
TLDR
A relevant body of evidence shows that tranylcypromine combined with first- and second- generation antipsychotics seems relatively safe and might have beneficial effects in some patients with depressive disorders, although caution is needed with some second-generation antipsychotic that have proserotonergic activity.
A Systematic Review of Available Evidence
TLDR
A relevant body of evidence shows that tranylcypromine combined with first and secondgeneration antipsychotics seems relatively safe and might have beneficial effects in some patients with depressive disorders, although caution is needed with some second-generation antippsychotics that have proserotonergic activity.
...
...

References

SHOWING 1-5 OF 5 REFERENCES
Ketamine induction and monoamine oxidase inhibitors.
  • D. Doyle
  • Medicine
    Journal of clinical anesthesia
  • 1990
Antidepressants do not increase the lethality of ketamine in mice.
TLDR
Mortality from ketamine was not increased by pretreatment with either type of antidepressant drugs, and non-fatal additive toxicity is not ruled out by these findings.